3653 results for «358»
3653 results
FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case
19 May 2026 – From EuroPCR 2026
A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.
Lesion preparation was performed with...
Behind standard practice: a place for DCB
19 May 2026 – From EuroPCR 2026
This session examines the role of drug-coated balloons (DCB) beyond standard practice in coronary revascularization. It includes discussions on revascularization strategies in young patients, rescue of early distal LIMA–LAD anastomosis, treatment of in-stent restenosis, stepwise complex CTO bifurcation revascularization using kissing DCBs, and management of calcified...
Identifying problems and solving complex anatomies during TAVI
19 May 2026 – From EuroPCR 2026
A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.
Mitral TEER beyond the routine: complex and complicated cases
19 May 2026 – From EuroPCR 2026
This session explores complex and complicated cases of mitral transcatheter edge-to-edge repair (TEER) beyond routine practice. It addresses challenges such as device failures, late complications, acute left ventricular dysfunction related to afterload changes, stepwise approaches to overcome procedural failures, rescue strategies in cardiogenic shock, and tailored...
Lessons learned to pave the way for future-proof strategies in TAVI
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session focuses on how current experience in transcatheter aortic valve implantation (TAVI) can be translated into more durable strategies for the future, particularly in patients with bicuspid aortic valve disease.
It provides a comprehensive overview of anatomical, clinical, and procedural considerations in this challenging...
From access to reperfusion: a procedural deep dive into pulmonary embolism
20 May 2026 – From EuroPCR 2026
From vascular access to reperfusion strategy, managing acute pulmonary embolism requires rapid decision-making, careful patient selection and increasingly sophisticated interventional techniques.
This EuroPCR 2026 session takes a procedural deep dive into contemporary pulmonary embolism management, focusing on thrombus aspiration techniques and the evolving role of computer-assisted vacuum...
Advancing mitral care with the Intrepid TMVR system
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the Intrepid transcatheter mitral valve replacement (TMVR) system and its role in expanding treatment options for patients with mitral regurgitation, including complex anatomies such as mitral annular calcification (MAC).
It highlights how the system’s design features and procedural imaging support a streamlined...
Seeing differently, treating better: advanced imaging shaping modern structural heart practice
20 May 2026 – From EuroPCR 2026
This session explores the transformative role of advanced imaging, particularly 3D intracardiac echocardiography (ICE), in modern structural heart interventions. It provides practical insights into implementation, highlighting how these tools can enhance workflow efficiency and procedural confidence across transcatheter edge-to-edge repair (TEER), left atrial appendage (LAA) closure,...
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...
Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
